Turning tumor macrophages from foes into allies A new CAR T therapy targets the immune cells that protect tumors, reshaping the tumor microenvironment and enabling host immune clearance. Written byBree Foster, PhD

Turning tumor macrophages from foes into allies A new CAR T therapy targets the immune cells that protect tumors, reshaping the tumor microenvironment and enabling host immune clearance. Written byBree Foster, PhD https://www.drugdiscoverynews.com/turning-tumor-macrophages-from-foes-into-allies-16970?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-92kdmX5amh13rjC4pji3KtCxF3s0ySfyMh80OsJ5YGvDNhhX3FEWPypY2aqRByUYKkuRNSmEKYKRzvyG5mrTU70qCHEA&_hsmi=435454106&utm_content=435454105&utm_source=hs_email Cancer immunotherapy has transformed oncology by harnessing the immune system to recognize and destroy tumors. Approaches such as immune checkpoint inhibitors and engineered immune cells have delivered durable responses in some patients — and nowhere more dramatically than CAR-T cell therapies in blood cancers. Several CAR-T treatments are now FDA-approved and have produced long-term remissions in leukemia and lymphoma.